"Compassionate Use Trials" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Providing an investigational therapy to a patient who is not eligible to receive that therapy in a clinical trial, but who has a serious or life-threatening illness for which other treatments are not available. Compassionate use trials allow patients to receive promising but not yet fully studied or approved therapies when no other treatment option exists. Also called expanded access trial.
| Descriptor ID |
D057176
|
| MeSH Number(s) |
E02.931.500 E05.337.300.199
|
| Concept/Terms |
Compassionate Use Trials- Compassionate Use Trials
- Compassionate Use Trial
- Trial, Compassionate Use
- Trials, Compassionate Use
- Use Trials, Compassionate
- Expanded Access Trials
- Access Trial, Expanded
- Expanded Access Trial
- Trial, Expanded Access
- Trials, Expanded Access
Humanitarian Device Exemption- Humanitarian Device Exemption
- Device Exemption, Humanitarian
- Device Exemptions, Humanitarian
- Exemption, Humanitarian Device
- Exemptions, Humanitarian Device
- Humanitarian Device Exemptions
|
Below are MeSH descriptors whose meaning is more general than "Compassionate Use Trials".
Below are MeSH descriptors whose meaning is more specific than "Compassionate Use Trials".
This graph shows the total number of publications written about "Compassionate Use Trials" by people in this website by year, and whether "Compassionate Use Trials" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 2 | 1 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Compassionate Use Trials" by people in Profiles.
-
Long-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access program. Epilepsia Open. 2024 Oct; 9(5):1816-1825.
-
Lessons Learned From the First-In-Human Compassionate Use of Connect-EA? in Ten Patients With Esophageal Atresia. J Pediatr Surg. 2024 Mar; 59(3):437-444.
-
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program. Epilepsia. 2023 08; 64(8):e156-e163.
-
An International Society for Cell & Gene Therapy working group short report on the future of expanded access to unapproved cell and gene therapies. Cytotherapy. 2023 07; 25(7):712-717.
-
Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrob Agents Chemother. 2022 03 15; 66(3):e0207121.
-
Safety and effectiveness of compassionate use of LARIAT? device for epicardial ligation of anatomically complex left atrial appendages. J Interv Card Electrophysiol. 2015 Jan; 42(1):11-9.
-
Placing and evaluating unproven interventions within a clinical ethical taxonomy of treatments for Ebola virus disease. Am J Bioeth. 2015; 15(4):50-3.
-
Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncol. 2015 Jan; 16(1):15-7.
-
Fish oil-based lipid emulsions in the treatment of parenteral nutrition-associated liver disease: an ongoing positive experience. Adv Nutr. 2014 Jan 01; 5(1):65-70.
-
Berlin Heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children. Circulation. 2013 Apr 23; 127(16):1702-11.